The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet.
Come see what’s next: https://t.co/sFtNEwV5yr. pic.twitter.com/UtxuabvPhx
— Gilead Sciences (@GileadSciences) February 24, 2020
This National HIV/AIDS and Aging Awareness Day, read about our work with #AgePositively partners @HealthHIV, @GMHC and @sageusa to support and create positive health outcomes for people living and aging with #HIV. #CreatingPossible #NHAAD
— Gilead Sciences (@GileadSciences) September 18, 2020
This #WorldLymphomaAwarenessDay, watch a video and read more about Shon, who received #CARTcell therapy to treat his advanced blood cancer. https://t.co/LtgAlaehnr #CreatingPossible #WLAD2020 pic.twitter.com/vrJmPgAQ0f
— Gilead Sciences (@GileadSciences) September 16, 2020
Today, we announced our investigational treatment for myelodysplastic syndrome was granted Breakthrough Therapy designation by the @US_FDA. https://t.co/areCvOxOR0 #bloodcancer #MDS
— Gilead Sciences (@GileadSciences) September 15, 2020
Today we announced we will acquire @ImmunomedicsInc, providing Gilead with a foundational, first-in-class commercial oncology product. https://t.co/9oTitIanDW. pic.twitter.com/NwWtr3EIjO
— Gilead Sciences (@GileadSciences) September 13, 2020
We can learn from each other’s successes as @FastTrackCities works to address HIV/AIDS globally. See how HIV advocates in São Paulo are taking a united approach to ending the city’s #HIV epidemic: https://t.co/YLPLamcsKE #FTC2020
— Gilead Sciences (@GileadSciences) September 10, 2020
In partnership with @IAPAC, we visited six @FastTrackCities that are accelerating their urban #HIV responses. Learn how the HIV community in London worked to surpass the UNAIDS 90:90:90 targets: https://t.co/A80WrhyiBM #FTC2020
— Gilead Sciences (@GileadSciences) September 9, 2020
One year ago today, we partnered with @ejaf to launch RADIAN at the #FTC2019 conference. RADIAN aims to address new HIV infections and deaths from AIDS-related illnesses in EECA by elevating local initiatives. Learn more: https://t.co/0u782QGTKf pic.twitter.com/rwUBe1p4iR
— Gilead Sciences (@GileadSciences) September 9, 2020
Our Chairman & CEO Daniel O’Day joined @IFPMA in a virtual event to discuss industry efforts to fight against #COVID19: https://t.co/vVjblAsYLn. https://t.co/0cyuoY0Wsg
— Gilead Sciences (@GileadSciences) September 3, 2020
In recognition of #BloodCancerAwarenessMonth, read what motivates Jan Pineda, Cell Therapy Specialist at @KitePharma, as she works on the front lines of the CAR T manufacturing process. #CreatingPossible #FightBloodCancer #BCAM
— Gilead Sciences (@GileadSciences) September 1, 2020
Gilead announced the @US_FDA expanded the Emergency Use Authorization of our investigational antiviral to now also include hospitalized patients with COVID-19 not requiring oxygen supplementation: https://t.co/J4WzqE2wJu.
— Gilead Sciences (@GileadSciences) August 29, 2020
“If we can help 100 patients, that’s not a little thing. I know in my heart this is the right thing to do.” Today during #ILC2020, read how Silvana Lesidrenska and @HepActive are working to improve care and support for people living with viral hepatitis in Bulgaria. #HBV
— Gilead Sciences (@GileadSciences) August 28, 2020
As part of our commitment to people with #liverdisease, we’re pleased to announce the launch of our #HBV TREAT Program. It aims to identify barriers to care and support the development of novel treatment pathways. Find out more: https://t.co/WJNe4gyhhu pic.twitter.com/tGR8MvDMNU
— Gilead Sciences (@GileadSciences) August 28, 2020
As we kick off #ILC2020, we’re proud to continue our work with people such as George Kalamitsis, who leads an innovative program for hepatitis C virus screening and linkage to care among hard-to-reach people in Athens.
— Gilead Sciences (@GileadSciences) August 27, 2020
Tomorrow at #ILC2020, our #viralhepatitis symposium will help the community re-imagine #liverdisease care and explore how health systems and providers have adapted amid #COVID19. Find out more: https://t.co/03hzLIbBmN. pic.twitter.com/EEzHhuxZDq
— Gilead Sciences (@GileadSciences) August 27, 2020
Read about how Gilead grantees @OakUndivided and @SCodeAcademy are working to eliminate the educational and #tech disparity among students and families in the SF Bay Area during the COVID-19 pandemic and beyond. #OaklandUndivided #LevelUp
— Gilead Sciences (@GileadSciences) August 25, 2020
Gilead is presenting new research on our viral hepatitis portfolio, alongside pipeline updates on our #HBV functional cure research program and #NASH, at The Digital #ILC2020 hosted by @EASLnews: https://t.co/x4GIxks0Sa.
— Gilead Sciences (@GileadSciences) August 25, 2020
Gilead has received a complete response letter from the U.S. FDA for our investigational treatment in #rheumatoidarthritis https://t.co/3jarrBGBn2
— Gilead Sciences (@GileadSciences) August 18, 2020
Gilead and Tango Therapeutics today announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer: https://t.co/sxbiISLRKl.
— Gilead Sciences (@GileadSciences) August 17, 2020
Gilead submits New Drug Application (NDA) to the @US_FDA for our investigational antiviral for the treatment of COVID-19: https://t.co/gRtShrWYHp. pic.twitter.com/nvgmmmcWMn
— Gilead Sciences (@GileadSciences) August 10, 2020
Since January, we have taken multiple steps to ramp up production and build supply of our investigational antiviral for the treatment of COVID-19. Read more about our expanded manufacturing network that now includes more than 40 companies worldwide: https://t.co/fI25bKWZnS.
— Gilead Sciences (@GileadSciences) August 6, 2020
Stigma has a real impact on people living with and at risk of contracting HIV. Combating the misinformation that leads to stigma is an essential part of efforts to end the HIV epidemic. View the results of our new survey with @GLAAD.
— Gilead Sciences (@GileadSciences) July 31, 2020
“The need for more education couldn't be clearer…If people don’t feel comfortable talking about HIV, then they won’t feel comfortable getting tested or seeking treatment.”
View the State of HIV Stigma Study released this week by Gilead’s @BeOurCOMPASS and @GLAAD. #EndHIVStigma
— Gilead Sciences (@GileadSciences) July 29, 2020
“We believe that our flexibility in deal structuring is a key advantage that will help us grow our existing portfolio with new assets.” Learn more about Gilead’s recent string of oncology deals and what’s next for the company from Devang Bhuva, SVP of Corporate Development.
— Gilead Sciences (@GileadSciences) July 29, 2020
In recognition of #WorldHepatitisDay, read an interview with Tram Tran, VP of Medical Affairs, who discusses her career-long dedication to liver disease, how the pandemic is affecting those with viral hepatitis and what must happen to make global progress toward elimination.
— Gilead Sciences (@GileadSciences) July 28, 2020
A new report by @BCG reveals 10 countries are on track to achieve #HCV elimination by 2030, but more progress is needed. With 10 years to go until the @WHO elimination goals, find out what countries can do to make elimination possible. https://t.co/14KF09LJzV #WorldHepatitisDay pic.twitter.com/i7sJ9Ei4wt
— Gilead Sciences (@GileadSciences) July 28, 2020
Learn more about our new partnership with Satcher Health Leadership Institute at @MSMEDU to study racial health inequities associated with COVID-19: https://t.co/BngHroVNPF. pic.twitter.com/aprIE7EPEm
— Gilead Sciences (@GileadSciences) July 28, 2020
COVID-19 data demonstrate that racial and ethnic minority groups, particularly Black Americans, are disproportionately impacted. Learn more about our new partnership with @MSMEDU to address racial health inequities associated with COVID-19: https://t.co/WH7uFONBET. pic.twitter.com/6gUcd2JJFZ
— Gilead Sciences (@GileadSciences) July 28, 2020
Read about George Kalamitsis, who runs an innovative program for hepatitis C virus screening and linkage to care among hard-to-reach people in Athens. Find out more about how his team empowers community members to engage with health services.
— Gilead Sciences (@GileadSciences) July 27, 2020
Read about Silvana Lesidrenska and @hepactive, an advocacy group dedicated to improving care and support for people with viral hepatitis in Bulgaria. Find out how the organization has helped reduce barriers to care and even changed national laws. https://t.co/ZWln3zntHg pic.twitter.com/20mhV1HhEW
— Gilead Sciences (@GileadSciences) July 25, 2020
Julie Di Paolo, Executive Director of Inflammation Biology at Gilead, is #CreatingPossible for those with #rheumatoidarthritis and other inflammatory diseases. Learn about her team’s progress in unlocking pathways to potentially improve patient outcomes: https://t.co/4lKcwoyekF.
— Gilead Sciences (@GileadSciences) July 24, 2020
Today we received a positive opinion from the #CHMP for our investigational treatment for moderate to severe #rheumatoidarthritis: https://t.co/UZW1rF16o4.
— Gilead Sciences (@GileadSciences) July 24, 2020
Continued scientific discovery can help improve HIV prevention strategies worldwide. Today, @TheLancet published the first and largest active-controlled study of PrEP medications. Learn more here: https://t.co/snU37MvXly.
— Gilead Sciences (@GileadSciences) July 23, 2020
Gilead today announced it has secured an exclusive option to acquire Tizona Therapeutics, a developer of first-in-class cancer immunotherapies: https://t.co/UvRMkruNEO. pic.twitter.com/ii3bcyl6w2
— Gilead Sciences (@GileadSciences) July 21, 2020
Gilead presents additional data on our investigational antiviral for the treatment of COVID-19 at the Virtual COVID-19 Conference as part of #AIDS2020Virtual: https://t.co/ZO3qd9GKeQ. pic.twitter.com/SMtb5f4vDm
— Gilead Sciences (@GileadSciences) July 10, 2020
We are proud to partner with the Elton John AIDS Foundation on RADIAN. Sir Elton John and David Furnish recently announced the first grantees of the RADIAN Model Cities program and Unmet Need Fund at #AIDS2020Virtual. Learn more: https://t.co/0u782QYv8P. pic.twitter.com/lYR6kLydKm
— Gilead Sciences (@GileadSciences) July 9, 2020
Today Gilead announced the initiation of a Phase 1a clinical study to evaluate an investigational inhaled solution of our antiviral for the treatment of COVID-19: https://t.co/4fhRydQRbT. pic.twitter.com/VaDZbGVkbJ
— Gilead Sciences (@GileadSciences) July 8, 2020
Learn more about the data we presented at #AIDS2020Virtual highlighting the potential impact of #COVID19 on #HIV prevention strategies and access to care: https://t.co/m1PzHuoB6I.
— Gilead Sciences (@GileadSciences) July 8, 2020
We're proud to announce new data evaluating treatment in a broad range of people living with #HIV. Learn more: https://t.co/RTYPnCFVAY. #AIDS2020Virtual
— Gilead Sciences (@GileadSciences) July 4, 2020
European Commission grants conditional marketing authorization for Gilead’s investigational antiviral for the treatment of COVID-19: https://t.co/RC5jcRwPSV. pic.twitter.com/by2hczUnNY
— Gilead Sciences (@GileadSciences) July 3, 2020
We’re excited to be sharing new data from our #HIV research and development program at #AIDS2020Virtual: https://t.co/uCbEPZMAFE.
— Gilead Sciences (@GileadSciences) July 1, 2020
We announced the price today for our investigational antiviral for the treatment of COVID-19. We believe our unique approach will provide broad and equitable access. Read more from our Chairman & CEO: https://t.co/rrEbrDxrLk. pic.twitter.com/9ElSExqSU3
— Gilead Sciences (@GileadSciences) June 29, 2020
Today is National #HIVTestingDay. We’re committed to raising awareness about the importance of HIV testing and early diagnosis. Learn more about testing options, including self-tests that can be done at home. https://t.co/KrxtM8ayNE
— Gilead Sciences (@GileadSciences) June 27, 2020
Our virology research teams committed to the field of emerging viruses more than five years ago, which helped position us to advance our investigational COVID-19 treatment when the pandemic began. Learn more from Tomas Cihlar, our VP of Virology: https://t.co/GupeWxH9y6 pic.twitter.com/ok1OnmAgO8
— Gilead Sciences (@GileadSciences) June 22, 2020
We are continuing to explore the full potential of our investigational antiviral for the treatment of COVID-19. Read more from our Chairman and CEO Daniel O’Day about the next wave of studies and our efforts to increase supply and ensure access.
— Gilead Sciences (@GileadSciences) June 22, 2020
Gilead has designed and will soon begin enrollment of an open-label, single-arm Phase 2/3 clinical trial of our investigational antiviral for the treatment of COVID-19 in pediatric patients with moderate-to-severe COVID-19. Read more: https://t.co/WcgBg5xQ9e. pic.twitter.com/IrLBELPgpS
— Gilead Sciences (@GileadSciences) June 17, 2020
Gilead announced today that Javier Rodriguez, CEO of @DaVita, has been appointed to our Board of Directors. Read more: https://t.co/1N7Kn2xLPS. pic.twitter.com/L6OgpT3x7f
— Gilead Sciences (@GileadSciences) June 16, 2020
We are heartened by the #SCOTUS decision affirming the #LGBTQ community has full workplace protection under the law. We are hopeful this ruling is a step closer to the #EqualityAct and a future where everyone who identifies as LGBTQ can live without fear of discrimination. https://t.co/v0qwpM3M5T
— Gilead Sciences (@GileadSciences) June 15, 2020
Gilead adds four additional generic manufacturers in Egypt and India to our non-exclusive voluntary licensing agreements to further expand supply of our investigational antiviral for COVID-19 in 127 countries. Learn more here: https://t.co/CiRPnx5O1N.
— Gilead Sciences (@GileadSciences) June 12, 2020
We recently introduced a program that enables our employees with medical backgrounds to take paid leave to volunteer in health settings in response to the COVID-19 pandemic. Read about Gilead employee Shayon Salehi’s experience volunteering in the UK: https://t.co/wivCfvhI91 pic.twitter.com/hYP2aSB17B
— Gilead Sciences (@GileadSciences) June 9, 2020
Data from our Phase 2 EQUATOR clinical program in #psoriaticarthritis will be presented today at #EULAR2020: https://t.co/Ez9Hj3ty7M. #PsA #biomarkers #inflammation
— Gilead Sciences (@GileadSciences) June 5, 2020
Today we shared results from our Phase 3 FINCH clinical program in #rheumatoidarthritis #RA: https://t.co/PRRzXraCcF
— Gilead Sciences (@GileadSciences) June 4, 2020
Gilead has been focused on rapidly studying the potential for our investigational antiviral to treat patients with COVID-19. Read more about the totality of clinical data to date: https://t.co/KnDN3DsScI.
— Gilead Sciences (@GileadSciences) June 1, 2020
Gilead announces results from Phase 3 trial of our investigational antiviral drug in patients with moderate COVID-19: https://t.co/Fmj5M0eUMt. pic.twitter.com/3b0JW7vgiT
— Gilead Sciences (@GileadSciences) June 1, 2020
At this weekend’s #ASCO20 meeting, we’re sharing updates across our immuno-oncology pipeline. Learn more in an interview with Pankaj Bhargava, our VP of Clinical Research who has been the ad-interim Therapeutic Area Head for Oncology at Gilead: https://t.co/85X1pLmLnB pic.twitter.com/U6COQaAy4o
— Gilead Sciences (@GileadSciences) May 30, 2020
The human gut contains tens of trillions of micro-organisms, and disruption in the gut #microbiome can be linked to conditions such as ulcerative colitis. For World Digestive Health Day, learn more about the microbiome from @WorldGastroOrg: https://t.co/UkWkVKMYRk. #WDHD2020 pic.twitter.com/XKXfXF67fS
— Gilead Sciences (@GileadSciences) May 29, 2020
Today we are presenting data for an investigational anti-CD47 antibody in myelodysplastic syndrome and acute myeloid leukemia at #ASCO20: https://t.co/uy6euWtEeE. pic.twitter.com/YugerLaeKN
— Gilead Sciences (@GileadSciences) May 29, 2020
Gilead and Arcus Biosciences establish 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies: https://t.co/RLxO2KWKU5. pic.twitter.com/vBQtg66XqU
— Gilead Sciences (@GileadSciences) May 27, 2020
Gilead statement on the @NEJM publication of data from the NIAID study of our investigational antiviral drug to treat COVID-19: https://t.co/b7cN7hTlyX. pic.twitter.com/e0UcdM8OKR
— Gilead Sciences (@GileadSciences) May 23, 2020
More than 300 million people worldwide live with at least one type of autoimmune arthritis. On #AiArthritisDay we recognize the resilience of individuals as they manage living with autoimmune conditions during the COVID-19 pandemic: https://t.co/PvEiJt9Tuy #ArthritisAwareness #RA
— Gilead Sciences (@GileadSciences) May 20, 2020
Today we announced topline results from the Phase 2B/3 SELECTION study in ulcerative colitis #IBD #Colitis: https://t.co/UUVMzy4dBJ.
— Gilead Sciences (@GileadSciences) May 20, 2020
Many years before COVID-19, our teams were working to help develop treatments for life-threatening viruses. Read about Gilead’s legacy in helping to address viral pandemics from the perspective of John Sayre, our SVP of Development Operations: https://t.co/eLFVVFU2WQ. pic.twitter.com/JfxVX6A8Pb
— Gilead Sciences (@GileadSciences) May 19, 2020
Inflammatory bowel disease can impact every part of a person’s life, from relationships to employment opportunities. This #WorldIBDDay2020 and every day, we’re committed to advancing care for those affected by IBD: https://t.co/hpI7cxbOPY. #MakeIBDWork pic.twitter.com/AVfGdxsYo9
— Gilead Sciences (@GileadSciences) May 19, 2020
Defeating #lymphoma will require a global collaboration. We are grateful to everyone involved in this fight and are proud to support @knowyournodes on World Lymphoma Awareness Day. #WLAD2020 pic.twitter.com/T8LgsKpfr8
— Kite, a Gilead Company (@KitePharma) September 15, 2020
#NEWS: Today, we submitted a supplemental biologics license application to @US_FDA for our #CARTcell therapy in relapsed or refractory indolent non-Hodgkin lymphomas
— Kite, a Gilead Company (@KitePharma) September 4, 2020
Kite CEO Christi Shaw reflects on her first year, lessons learned and the advancements made to support people living with #cancer
— Kite, a Gilead Company (@KitePharma) August 10, 2020
#BREAKING: Today, the @US_FDA granted accelerated approval of our second #CARTcell therapy.
— Kite, a Gilead Company (@KitePharma) July 24, 2020
#ICYMI: Our new European manufacturing facility brings #celltherapy production closer to patients in Europe and the surrounding regions, reducing the time it takes #CARTcells to reach patients by almost a week.
— Kite, a Gilead Company (@KitePharma) July 22, 2020
Our singular focus is #celltherapy, which we believe has the potential to change the way #cancer is treated
— Kite, a Gilead Company (@KitePharma) July 20, 2020
Kite’s new European manufacturing facility will help streamline the #CARTcell manufacturing process, reducing the time it takes to return cells to patients in Europe and the surrounding regions by almost a week
— Kite, a Gilead Company (@KitePharma) June 12, 2020
At Kite, our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy
— Kite, a Gilead Company (@KitePharma) May 28, 2020
Moderate-COVID remdesivir trial from @GileadSciences out in @JAMA_current today. https://t.co/mrMUjYv9tV
— Steve Joffe (@SteveJoffe) September 16, 2020
This isn't the fun content I know you all crave, but this is more important to share. @GileadSciences is charging between $2k and $3k for their COVID-19 drug, which cost $1 per vial to make. Treasurer Torsella is gathering treasurers to fight back.https://t.co/lyJSsx7jZP
— Pennsylvania Treasury (@PATreasury) September 17, 2020
.@GileadSciences Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout
– by @frankvinluan https://t.co/kxZsYFCzQ6$GILD $IMMU— Xconomy (@Xconomy) September 14, 2020